Zydena Contraindications

Use of Zydena is contraindicated in patients with known hypersensitivity to any component of the tablet.
Zydena has been shown to potentiate the hypotensive effects of acute and chronic nitrates, and its co-administration with nitric oxide donors, organic nitrates or organic nitrites in any form, either regularly or intermittently, is therefore contraindicated (see Precautions).
Zydena is contraindicated in patients with congenital QT prolongation syndrome, or who are on drugs that increase QT interval. Patients administering potent cytochrome P450 3A4 inhibitors (HIV protease inhibitor indinavir or ritonavir) are also contraindicated from Zydena.
Zydena is contraindicated in men for whom sexual activity is inadvisable due to underlying cardiovascular diseases (e.g. unstable angina or severe heart failure) (see Precautions). The possibility of undiagnosed cardiovascular disorders in men with erectile dysfunction should be considered before prescribing Zydena.
The safety of udenafil has not been studied in the following sub-groups of patients and therefore its use is contraindicated until further information is available: severe liver failure, renal failure, hypotension (blood pressure <90/50 mmHg), uncontrolled hypertension (blood pressure >170/100 mmHg), uncontrolled arrhythmias, stroke, myocardial infarction or a history of coronary artery bypass surgery within the last 6 months and known hereditary degenerative retinal disorders including retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).
The efficacy and safety of combinations of Zydena and other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.
Because Zydena contains lactose, patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not administer Zydena.
Patients under 18 years of age are contraindicated from using Zydena.
Concomitant use of Zydena and a Guanylate Cyclase (GC) stimulator (e.g. riociguat) is contraindicated, as PDE5 inhibitors, including Zydena, may potentiate the hypotensive effects of GC stimulators.